Bioengineered Kidney Tissue Implant
End-Stage Renal Disease (ESRD)
Pre-clinicalActive
Key Facts
About Trestle Biotherapeutics
Trestle Biotherapeutics is an ambitious, early-stage biotech focused on transforming the treatment of kidney failure through tissue engineering. The company is developing an implantable bioengineered tissue designed to restore kidney function, addressing a massive unmet need for the over 850,000 patients worldwide dependent on dialysis. Led by a seasoned team with deep expertise in 3D bioprinting and stem cell biology from Organovo, Trestle is building a platform that could eventually be applied to other organ systems. The company is currently in the preclinical development phase and is backed by undisclosed advisors and investors.
View full company profileTherapeutic Areas
Other End-Stage Renal Disease (ESRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SURDIAL™ DX Hemodialysis System | Nipro Medical | Commercial |
| Bioartificial Kidney | IVIVA Medical | Pre-clinical |
| SCD-Adult | SeaStar Medical | Investigational |